Loading...
Loading...
CYCN| Name | Value |
|---|---|
| Revenues | 1,625.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 1,625.0K |
| Operating Expense | 7,348.0K |
| Operating I/L | -7,348.0K |
| Other Income/Expense | 132.0K |
| Interest Income | 0.0K |
| Pretax | -7,216.0K |
| Income Tax Expense | -183.0K |
| Net Income/Loss | -7,033.0K |
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious central nervous system (CNS) diseases. Its lead product candidate, CY6463, is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology. The company also develops Praliciguat for resistant hypertension and diabetic nephropathy, Olinciguat for sickle cell disease, and CY3018 for CNS disorders. Cyclerion generates revenue through the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including compound and related forms, often through licensing agreements with other companies.
